{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T03:25:37Z","timestamp":1793330737923,"version":"4.5.0"},"reference-count":21,"publisher":"American Society of Hematology","issue":"18","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,10,29]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Clinical evaluation of B-cell maturation antigen chimeric antigen receptor T-cell therapy in 4 patients with refractory primary immune thrombocytopenia demonstrated manageable safety, rapid and sustained platelet recovery, and durable drug-free complete remission lasting up to 15 months. This trial was registered at www.clinicaltrials.gov as NCT06519565.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/blood.2026035047","type":"journal-article","created":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T02:15:13Z","timestamp":1784945713000},"page":"2306-2312","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":2,"title":["BCMA-directed CAR T-cell therapy induces durable drug-free remission in refractory primary immune thrombocytopenia"],"prefix":"10.1182","volume":"148","author":[{"given":"Jinhui","family":"Shu","sequence":"first","affiliation":[{"name":"1Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China"},{"name":"2Hubei Clinical Medical Center of Cell Therapy for Neoplastic Disease, Wuhan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Xu","sequence":"additional","affiliation":[{"name":"1Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China"},{"name":"2Hubei Clinical Medical Center of Cell Therapy for Neoplastic Disease, Wuhan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peiru","family":"Li","sequence":"additional","affiliation":[{"name":"1Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China"},{"name":"2Hubei Clinical Medical Center of Cell Therapy for Neoplastic Disease, Wuhan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Xie","sequence":"additional","affiliation":[{"name":"1Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China"},{"name":"2Hubei Clinical Medical Center of Cell Therapy for Neoplastic Disease, Wuhan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Liu","sequence":"additional","affiliation":[{"name":"1Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China"},{"name":"2Hubei Clinical Medical Center of Cell Therapy for Neoplastic Disease, Wuhan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongjian","family":"Li","sequence":"additional","affiliation":[{"name":"3Shenzhen Pregene Biopharma Company, Shenzhen, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2884-9247","authenticated-orcid":false,"given":"James B.","family":"Bussel","sequence":"additional","affiliation":[{"name":"4Division of Pediatric Hematology and Oncology, Department of Pediatrics, Weill Cornell Medicine, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2815-4568","authenticated-orcid":false,"given":"Yu","family":"Hu","sequence":"additional","affiliation":[{"name":"1Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China"},{"name":"2Hubei Clinical Medical Center of Cell Therapy for Neoplastic Disease, Wuhan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7941-2443","authenticated-orcid":false,"given":"Heng","family":"Mei","sequence":"additional","affiliation":[{"name":"1Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China"},{"name":"2Hubei Clinical Medical Center of Cell Therapy for Neoplastic Disease, Wuhan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2026102911213694800_bib1","doi-asserted-by":"crossref","first-page":"101389","DOI":"10.1016\/j.blre.2026.101389","article-title":"The humoral pathophysiology of immune thrombocytopenia: how close are we to patient-specific disease treatment?","volume":"77","author":"Norris","year":"2026","journal-title":"Blood Rev"},{"issue":"12","key":"2026102911213694800_bib2","doi-asserted-by":"crossref","first-page":"103677","DOI":"10.1016\/j.autrev.2024.103677","article-title":"Autoimmune effector mechanisms associated with a defective immunosuppressive axis in immune thrombocytopenia (ITP)","volume":"23","author":"Li","year":"2024","journal-title":"Autoimmun Rev"},{"issue":"589","key":"2026102911213694800_bib3","doi-asserted-by":"crossref","first-page":"eabc3961","DOI":"10.1126\/scitranslmed.abc3961","article-title":"Rituximab-resistant splenic memory B cells and newly engaged naive B cells fuel relapses in patients with immune thrombocytopenia","volume":"13","author":"Crickx","year":"2021","journal-title":"Sci Transl Med"},{"issue":"1","key":"2026102911213694800_bib4","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1136\/ard-2024-226142","article-title":"CD19-CAR T-cell therapy induces deep tissue depletion of B cells","volume":"84","author":"Tur","year":"2025","journal-title":"Ann Rheum Dis"},{"issue":"20","key":"2026102911213694800_bib5","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1056\/NEJMc2501527","article-title":"Daratumumab in relapsed or refractory pediatric immune thrombocytopenia","volume":"392","author":"Sun","year":"2025","journal-title":"N Engl J Med"},{"issue":"23","key":"2026102911213694800_bib6","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1056\/NEJMoa2400409","article-title":"A novel anti-CD38 monoclonal antibody for treating immune thrombocytopenia","volume":"390","author":"Chen","year":"2024","journal-title":"N Engl J Med"},{"issue":"8","key":"2026102911213694800_bib7","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1056\/NEJMoa2308917","article-title":"CD19 CAR T-cell therapy in autoimmune disease - a case series with follow-up","volume":"390","author":"M\u00fcller","year":"2024","journal-title":"N Engl J Med"},{"issue":"10472","key":"2026102911213694800_bib8","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0140-6736(24)02504-2","article-title":"Salvage treatment of multi-refractory primary immune thrombocytopenia with CD19 CAR T cells","volume":"405","author":"Trautmann-Grill","year":"2025","journal-title":"Lancet"},{"issue":"3","key":"2026102911213694800_bib9","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1182\/blood-2016-01-694356","article-title":"Persistence of long-lived plasma cells and humoral immunity in individuals responding to CD19-directed CAR T-cell therapy","volume":"128","author":"Bhoj","year":"2016","journal-title":"Blood"},{"issue":"23","key":"2026102911213694800_bib10","doi-asserted-by":"crossref","first-page":"6414","DOI":"10.1016\/j.cell.2025.09.020","article-title":"Anti-BCMA CAR-T therapy in patients with progressive multiple sclerosis","volume":"188","author":"Qin","year":"2025","journal-title":"Cell"},{"issue":"6","key":"2026102911213694800_bib11","doi-asserted-by":"crossref","first-page":"e2315990121","DOI":"10.1073\/pnas.2315990121","article-title":"Single-cell analysis of refractory anti-SRP necrotizing myopathy treated with anti-BCMA CAR-T cell therapy","volume":"121","author":"Qin","year":"2024","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"10527","key":"2026102911213694800_bib12","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/S0140-6736(25)02515-2","article-title":"BCMA-CD3 T-cell engager as salvage therapy for multirefractory primary immune thrombocytopenia","volume":"407","author":"Duque-Afonso","year":"2026","journal-title":"Lancet"},{"issue":"12","key":"2026102911213694800_bib13","doi-asserted-by":"crossref","first-page":"e153580","DOI":"10.1172\/JCI153580","article-title":"High-affinity autoreactive plasma cells disseminate through multiple organs in patients with immune thrombocytopenic purpura","volume":"132","author":"Canales-Herrerias","year":"2022","journal-title":"J Clin Invest"},{"issue":"1","key":"2026102911213694800_bib14","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/s41408-024-01193-6","article-title":"Impact of T cell characteristics on CAR-T cell therapy in hematological malignancies","volume":"14","author":"Tao","year":"2024","journal-title":"Blood Cancer J"},{"issue":"1","key":"2026102911213694800_bib15","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1182\/bloodadvances.2019000868","article-title":"A modern reassessment of glycoprotein-specific direct platelet autoantibody testing in immune thrombocytopenia","volume":"4","author":"Al-Samkari","year":"2020","journal-title":"Blood Adv"},{"issue":"4","key":"2026102911213694800_bib16","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1038\/s41551-026-01633-7","article-title":"Predictive biomarkers of response to chimeric antigen receptor (CAR) T-cell therapy for pan-haematologic cancer","volume":"10","author":"Chen","year":"2026","journal-title":"Nat Biomed Eng"},{"issue":"9","key":"2026102911213694800_bib17","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1158\/2159-8290.CD-20-1677","article-title":"Integrative bulk and single-cell profiling of premanufacture T-cell populations reveals factors mediating long-term persistence of CAR T-cell therapy","volume":"11","author":"Chen","year":"2021","journal-title":"Cancer Discov"},{"issue":"3","key":"2026102911213694800_bib18","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1182\/blood-2010-05-286286","article-title":"Human effector CD8+ T cells derived from naive rather than memory subsets possess superior traits for adoptive immunotherapy","volume":"117","author":"Hinrichs","year":"2011","journal-title":"Blood"},{"issue":"6","key":"2026102911213694800_bib19","first-page":"304.e1","article-title":"Pathogen-specific humoral immunity and infections in B cell maturation antigen-directed chimeric antigen receptor T cell therapy recipients with multiple myeloma","volume":"28","author":"Josyula","year":"2022","journal-title":"Transpl Cell Ther"},{"issue":"10","key":"2026102911213694800_bib20","first-page":"955","article-title":"Best practice considerations by The American Society of Transplant and Cellular Therapy: infection prevention and management after chimeric antigen receptor T cell therapy for hematological malignancies","volume":"30","author":"Shahid","year":"2024","journal-title":"Transpl Cell Ther"},{"issue":"1","key":"2026102911213694800_bib21","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1038\/s41408-025-01321-w","article-title":"Humoral vaccine responses following chimeric antigen receptor T-cell therapy for hematological malignancies","volume":"15","author":"Einarsdottir","year":"2025","journal-title":"Blood Cancer J"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/148\/18\/2306\/2596937\/blood_bld-2026-035047-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/148\/18\/2306\/2596937\/blood_bld-2026-035047-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T15:21:43Z","timestamp":1793287303000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/148\/18\/2306\/569874\/BCMA-directed-CAR-T-cell-therapy-induces-durable"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,29]]},"references-count":21,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2026,10,29]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2026035047","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,10,29]]},"published":{"date-parts":[[2026,10,29]]}}}